ADAM17 and neoplasm: Immunosuppression of T-cell response by MDSC may be accomplished through cleavage of L-selectin on CD4+ and CD8+ T-cells by ADAM metallopeptidase domain 17 (ADAM17) and disintegrin thus impairing T-cell trafficking to tumor sites (50).